GRATRY & Co LLC lowered its position in shares of Icon Plc (NASDAQ:ICLR) by 2.4% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 28,670 shares of the medical research company’s stock after selling 715 shares during the period. Icon Plc comprises about 3.4% of GRATRY & Co LLC’s portfolio, making the stock its 2nd biggest position. GRATRY & Co LLC owned about 0.05% of Icon Plc worth $2,804,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. IHT Wealth Management LLC grew its position in Icon Plc by 16.9% during the 2nd quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock worth $223,000 after acquiring an additional 24 shares during the last quarter. IFP Advisors Inc grew its position in Icon Plc by 3.0% during the 2nd quarter. IFP Advisors Inc now owns 2,299 shares of the medical research company’s stock worth $225,000 after acquiring an additional 67 shares during the last quarter. Huntington National Bank grew its position in Icon Plc by 5.0% during the 2nd quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock worth $159,000 after acquiring an additional 77 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its position in Icon Plc by 5.0% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 3,537 shares of the medical research company’s stock worth $282,000 after acquiring an additional 168 shares during the last quarter. Finally, Acrospire Investment Management LLC grew its position in Icon Plc by 20.1% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock worth $117,000 after acquiring an additional 200 shares during the last quarter. Institutional investors and hedge funds own 91.53% of the company’s stock.

Icon Plc (ICLR) traded down 0.50% during midday trading on Friday, hitting $114.28. The company’s stock had a trading volume of 79,475 shares. Icon Plc has a 52-week low of $73.76 and a 52-week high of $117.53. The company has a market cap of $6.18 billion, a PE ratio of 23.18 and a beta of 0.59. The stock has a 50 day moving average of $112.86 and a 200 day moving average of $97.82.

Icon Plc (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, July 27th. The medical research company reported $1.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.01. The business had revenue of $431.00 million for the quarter, compared to analysts’ expectations of $430.68 million. Icon Plc had a return on equity of 28.72% and a net margin of 15.97%. The business’s revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.14 EPS. On average, equities analysts expect that Icon Plc will post $5.32 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/13/gratry-co-llc-sells-715-shares-of-icon-plc-iclr.html.

ICLR has been the topic of a number of research reports. BidaskClub lowered Icon Plc from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 16th. Jefferies Group LLC upgraded Icon Plc from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $86.00 to $117.00 in a research report on Thursday, June 29th. Goldman Sachs Group, Inc. (The) upgraded Icon Plc from a “buy” rating to a “conviction-buy” rating and set a $117.00 price target on the stock in a research report on Friday, July 7th. Mizuho upped their price target on Icon Plc from $104.00 to $108.00 and gave the company a “neutral” rating in a research report on Thursday, July 27th. Finally, Credit Suisse Group reiterated a “buy” rating on shares of Icon Plc in a research report on Friday, July 28th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. Icon Plc currently has an average rating of “Buy” and an average price target of $117.33.

About Icon Plc

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Institutional Ownership by Quarter for Icon Plc (NASDAQ:ICLR)

Receive News & Stock Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related stocks with our FREE daily email newsletter.